{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T01:16:04Z","timestamp":1789434964571,"version":"build-2803163510"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,2,27]],"date-time":"2020-02-27T00:00:00Z","timestamp":1582761600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,2,27]],"date-time":"2020-02-27T00:00:00Z","timestamp":1582761600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"NIH Center Core Grant","award":["P30EY014801"],"award-info":[{"award-number":["P30EY014801"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Ophthal Inflamm Infect"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>To assess the in-vitro efficacy of delafloxacin, a new fourth generation fluoroquinolone, against <jats:italic>Staphylococcus<\/jats:italic> vitreous isolates from patients with clinically diagnosed endophthalmitis. This is the first investigation of delafloxacin in ocular tissues.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>Intravitreal isolates of culture-proven <jats:italic>S. aureus<\/jats:italic> and <jats:italic>S. epidermidis<\/jats:italic> were identified between 2014 and 2018. Minimum inhibitor concentrations (MIC) were determined using ETEST strips. The antibiotic susceptibilities were tested against a panel of drugs including glycopeptides such as vancomycin, as well as traditional and newer fluoroquinolones (levofloxacin, moxifloxacin, and delafloxacin).<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>Of 45 total isolates identified between 2014 and 2018, 13% (6) were methicillin-resistant <jats:italic>S. aureus<\/jats:italic> (MRSA), 9% (4) were methicillin-sensitive <jats:italic>S. aureus<\/jats:italic> (MSSA), 53% (24) were methicillin-resistant <jats:italic>S. epidermidis<\/jats:italic> (MRSE), and 24% (11) were methicillin-sensitive <jats:italic>S. epidermidis<\/jats:italic> (MSSE). Among the fluoroquinolones, resistance rates were 61% for levofloxacin, 50% for moxifloxacin, and 12% for delafloxacin. Inter-class comparisons between delafloxacin and the two other fluoroquinolones demonstrated higher Gram-positive susceptibility to delafloxacin (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.01). MIC90 values were lowest for delafloxacin (1.0\u2009\u03bcg\/mL) compared to levofloxacin (8.0\u2009\u03bcg\/mL) and moxifloxacin (8.0\u2009\u03bcg\/mL). Vancomycin was 100% effective against all isolates with MIC90 value of 0.75\u2009\u03bcg\/mL.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusion<\/jats:title>\n<jats:p>Compared to levofloxacin and moxifloxacin, the newer fluoroquinolone delafloxacin demonstrated the lowest MICs values and lowest rates of resistance for Gram-positive in-vitro <jats:italic>S. epidermidis<\/jats:italic> and <jats:italic>S. aureus<\/jats:italic> vitreous isolates.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s12348-020-0200-0","type":"journal-article","created":{"date-parts":[[2020,2,27]],"date-time":"2020-02-27T00:09:11Z","timestamp":1582762151000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["In vitro Susceptibilities of Methicillin-Susceptible and Resistant Staphylococci to Traditional Antibiotics Compared to a Novel Fluoroquinolone"],"prefix":"10.1186","volume":"10","author":[{"given":"Kenneth C.","family":"Fan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas A.","family":"Yannuzzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hasenin","family":"Al-Khersan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nimesh A.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Maestre-Mesa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mustafa","family":"Zaidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darlene","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9990-7467","authenticated-orcid":false,"suffix":"Jr","given":"Harry W.","family":"Flynn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,2,27]]},"reference":[{"issue":"3","key":"200_CR1","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1128\/CMR.00113-16","volume":"30","author":"ML Durand","year":"2017","unstructured":"Durand ML (2017) Bacterial and fungal endophthalmitis. Clin Microbiol Rev. 30(3):597\u2013613","journal-title":"Clin Microbiol Rev."},{"issue":"2","key":"200_CR2","doi-asserted-by":"publisher","first-page":"143","DOI":"10.3928\/23258160-20140306-08","volume":"45","author":"JB Fileta","year":"2014","unstructured":"Fileta JB, Scott IU, Flynn HW Jr (2014) Meta-analysis of infectious endophthalmitis after intravitreal injection of anti-vascular endothelial growth factor agents. Ophthalmic Surg Lasers Imaging Retina. 45(2):143\u2013149","journal-title":"Ophthalmic Surg Lasers Imaging Retina."},{"issue":"4","key":"200_CR3","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1016\/j.ajo.2008.10.023","volume":"147","author":"CM Andreoli","year":"2009","unstructured":"Andreoli CM, Andreoli MT, Kloek CE, Ahuero AE, Vavvas D, Durand ML (2009) Low rate of endophthalmitis in a large series of open globe injuries. Am J Ophthalmol. 147(4):601\u2013608 e2","journal-title":"Am J Ophthalmol."},{"issue":"4","key":"200_CR4","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1097\/IAE.0b013e31820a67e4","volume":"31","author":"CA McCannel","year":"2011","unstructured":"McCannel CA (2011) Meta-analysis of endophthalmitis after intravitreal injection of anti-vascular endothelial growth factor agents: causative organisms and possible prevention strategies. Retina. 31(4):654\u2013661","journal-title":"Retina."},{"issue":"1","key":"200_CR5","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/S0002-9394(03)00896-1","volume":"137","author":"MS Benz","year":"2004","unstructured":"Benz MS, Scott IU, Flynn HW Jr, Unonius N, Miller D (2004) Endophthalmitis isolates and antibiotic sensitivities: a 6-year review of culture-proven cases. Am J Ophthalmol. 137(1):38\u201342","journal-title":"Am J Ophthalmol."},{"key":"200_CR6","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.ajo.2016.11.006","volume":"174","author":"NA Yannuzzi","year":"2017","unstructured":"Yannuzzi NA, Si N, Relhan N, Kuriyan AE, Albini TA, Berrocal AM, Davis JL, Smiddy WE, Townsend J, Miller D, Flynn HW Jr (2017) Endophthalmitis after clear corneal cataract surgery: outcomes over two decades. Am J Ophthalmol. 174:155\u2013159","journal-title":"Am J Ophthalmol."},{"issue":"7","key":"200_CR7","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1001\/jamaophthalmol.2017.1826","volume":"135","author":"JD Stringham","year":"2017","unstructured":"Stringham JD, Relhan N, Miller D, Flynn HW Jr (2017) Trends in fluoroquinolone nonsusceptibility among coagulase-negative Staphylococcus isolates causing endophthalmitis, 1995-2016. JAMA Ophthalmol. 135(7):814\u2013815","journal-title":"JAMA Ophthalmol."},{"issue":"12","key":"200_CR8","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1001\/archophthalmol.2012.2348","volume":"130","author":"AM Schimel","year":"2012","unstructured":"Schimel AM, Miller D, Flynn HW (2012) Evolving fluoroquinolone resistance among coagulase-negative Staphylococcus isolates causing endophthalmitis. Arch Ophthalmol. 130(12):1617\u20131618","journal-title":"Arch Ophthalmol."},{"issue":"8","key":"200_CR9","doi-asserted-by":"publisher","first-page":"1634","DOI":"10.1016\/j.ophtha.2014.02.001","volume":"121","author":"RC Gentile","year":"2014","unstructured":"Gentile RC, Shukla S, Shah M, Ritterband DC, Engelbert M, Davis A, Hu DN (2014) Microbiological spectrum and antibiotic sensitivity in endophthalmitis: a 25-year review. Ophthalmology. 121(8):1634\u20131642","journal-title":"Ophthalmology."},{"issue":"3","key":"200_CR10","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1001\/archopht.123.3.341","volume":"123","author":"FM Recchia","year":"2005","unstructured":"Recchia FM, Busbee BG, Pearlman RB, Carvalho-Recchia CA, Ho AC (2005) Changing trends in the microbiologic aspects of postcataract endophthalmitis. Arch Ophthalmol. 123(3):341\u2013346","journal-title":"Arch Ophthalmol."},{"issue":"5","key":"200_CR11","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1016\/j.ajo.2006.05.044","volume":"142","author":"VA Deramo","year":"2006","unstructured":"Deramo VA, Lai JC, Fastenberg DM, Udell IJ (2006) Acute endophthalmitis in eyes treated prophylactically with gatifloxacin and moxifloxacin. Am J Ophthalmol. 142(5):721\u2013725","journal-title":"Am J Ophthalmol."},{"key":"200_CR12","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.2217\/fmb-2018-0067","volume":"13","author":"M Bassetti","year":"2018","unstructured":"Bassetti M, Righi E, Pecori D, Tillotson G (2018) Delafloxacin: an improved fluoroquinolone developed through advanced molecular engineering. Future Microbiol. 13:1081\u20131094","journal-title":"Future Microbiol."},{"issue":"12","key":"200_CR13","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1001\/archopht.1995.01100120009001","volume":"113","author":"Endophthalmitis Vitrectomy Study Group","year":"1995","unstructured":"Endophthalmitis Vitrectomy Study Group (1995) Results of the endophthalmitis vitrectomy study. A randomized trial of immediate vitrectomy and of intravenous antibiotics for the treatment of postoperative bacterial endophthalmitis. Arch Ophthalmol 113(12):1479\u20131496","journal-title":"Arch Ophthalmol"},{"issue":"1","key":"200_CR14","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1001\/archopht.1994.01090130028003","volume":"112","author":"TM Aaberg Jr","year":"1994","unstructured":"Aaberg TM Jr, Flynn HW Jr, Murray TG (1994) Intraocular ceftazidime as an alternative to the aminoglycosides in the treatment of endophthalmitis. Arch Ophthalmol. 112(1):18\u201319","journal-title":"Arch Ophthalmol."},{"issue":"5","key":"200_CR15","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1016\/j.survophthal.2018.02.003","volume":"63","author":"B Clarke","year":"2018","unstructured":"Clarke B, Williamson TH, Gini G, Gupta B (2018) Management of bacterial postoperative endophthalmitis and the role of vitrectomy. Surv Ophthalmol. 63(5):677\u2013693","journal-title":"Surv Ophthalmol."},{"issue":"3","key":"200_CR16","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1080\/02713683.2016.1188118","volume":"42","author":"C Liu","year":"2017","unstructured":"Liu C, Ji J, Li S, Wang Z, Tang L, Cao W, Sun X (2017) Microbiological isolates and antibiotic susceptibilities: a 10-year review of culture-proven endophthalmitis cases. Curr Eye Res. 42(3):443\u2013447","journal-title":"Curr Eye Res."},{"issue":"11","key":"200_CR17","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1038\/sj.eye.6702094","volume":"20","author":"V Vedantham","year":"2006","unstructured":"Vedantham V, Lalitha P, Velpandian T, Ghose S, Mahalakshmi R, Ramasamy K (2006) Vitreous and aqueous penetration of orally administered moxifloxacin in humans. Eye (Lond). 20(11):1273\u20131278","journal-title":"Eye (Lond)."},{"issue":"6","key":"200_CR18","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1016\/j.cmi.2015.01.028","volume":"21","author":"C Chiquet","year":"2015","unstructured":"Chiquet C, Maurin M, Altayrac J, Aptel F, Boisset S, Vandenesch F, Cornut PL, Romanet JP, Gain P, Carricajo A (2015) Correlation between clinical data and antibiotic resistance in coagulase-negative Staphylococcus species isolated from 68 patients with acute post-cataract endophthalmitis. Clin Microbiol Infect 21(6):592 e1-8","journal-title":"Clin Microbiol Infect"},{"issue":"3","key":"200_CR19","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1007\/s13318-018-0520-8","volume":"44","author":"J Shiu","year":"2019","unstructured":"Shiu J, Ting G, Kiang TK (2019) Clinical pharmacokinetics and pharmacodynamics of delafloxacin. Eur J Drug Metab Pharmacokinet. 44(3):305\u2013317","journal-title":"Eur J Drug Metab Pharmacokinet."},{"key":"200_CR20","doi-asserted-by":"crossref","unstructured":"Zhao M, Lepak AJ, Marchillo K, Andes DR (2019) In vivo pharmacodynamic target determination for delafloxacin against Klebsiella pneumoniae and Pseudomonas aeruginosa in the neutropenic murine pneumonia model. Antimicrob Agents Chemother. 63(10)","DOI":"10.1128\/AAC.01131-19"},{"issue":"2","key":"200_CR21","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/s40121-018-0198-x","volume":"7","author":"SCJ Jorgensen","year":"2018","unstructured":"Jorgensen SCJ, Mercuro NJ, Davis SL, Rybak MJ (2018) Delafloxacin: place in therapy and review of microbiologic, clinical and pharmacologic properties. Infect Dis Ther. 7(2):197\u2013217","journal-title":"Infect Dis Ther."},{"issue":"5","key":"200_CR22","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1093\/cid\/ciy165","volume":"67","author":"W O\u2019Riordan","year":"2018","unstructured":"O\u2019Riordan W, Mc Manus A, Teras J, Poromanski I, Cruz-Saldariagga M, Quintas M, Lawrence L, Liang S, Cammarata S, Group PS (2018) A comparison of the efficacy and safety of intravenous followed by oral delafloxacin with vancomycin plus aztreonam for the treatment of acute bacterial skin and skin structure infections: a phase 3, multinational, double-blind, randomized study. Clin Infect Dis. 67(5):657\u2013666","journal-title":"Clin Infect Dis."},{"key":"200_CR23","doi-asserted-by":"crossref","unstructured":"McCurdy S, Lawrence L, Quintas M, Woosley L, Flamm R, Tseng C, Cammarata S (2017) In vitro activity of delafloxacin and microbiological response against fluoroquinolone-susceptible and nonsusceptible Staphylococcus aureus isolates from two phase 3 studies of acute bacterial skin and skin structure infections. Antimicrob Agents Chemother. 61(9)","DOI":"10.1128\/AAC.00772-17"},{"issue":"3","key":"200_CR24","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1007\/s10792-016-0288-2","volume":"37","author":"YT Teng","year":"2017","unstructured":"Teng YT, Teng MC, Kuo HK, Fang PC, Wu PC, Chen CH, Kuo MT, Yang IH, Chen YJ (2017) Isolates and antibiotic susceptibilities of endophthalmitis in postcataract surgery: a 12-year review of culture-proven cases. Int Ophthalmol. 37(3):513\u2013518","journal-title":"Int Ophthalmol."},{"issue":"10","key":"200_CR25","doi-asserted-by":"publisher","first-page":"3260","DOI":"10.1128\/AAC.47.10.3260-3269.2003","volume":"47","author":"AM Nilius","year":"2003","unstructured":"Nilius AM, Shen LL, Hensey-Rudloff D, Almer LS, Beyer JM, Balli DJ, Cai Y, Flamm RK (2003) In vitro antibacterial potency and spectrum of ABT-492, a new fluoroquinolone. Antimicrob Agents Chemother. 47(10):3260\u20133269","journal-title":"Antimicrob Agents Chemother."},{"issue":"6","key":"200_CR26","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1093\/cid\/ciy600","volume":"68","author":"LD Saravolatz","year":"2019","unstructured":"Saravolatz LD, Stein GE (2019) Delafloxacin: a new anti-methicillin-resistant Staphylococcus aureus fluoroquinolone. Clin Infect Dis. 68(6):1058\u20131062","journal-title":"Clin Infect Dis."}],"container-title":["Journal of Ophthalmic Inflammation and Infection"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12348-020-0200-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12348-020-0200-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12348-020-0200-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,26]],"date-time":"2021-02-26T00:07:30Z","timestamp":1614298050000},"score":1,"resource":{"primary":{"URL":"https:\/\/joii-journal.springeropen.com\/articles\/10.1186\/s12348-020-0200-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,27]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["200"],"URL":"https:\/\/doi.org\/10.1186\/s12348-020-0200-0","relation":{},"ISSN":["1869-5760"],"issn-type":[{"value":"1869-5760","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,27]]},"assertion":[{"value":"7 September 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 February 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 February 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Institutional review board approval was obtained from the University of Miami Miller School of Medicine Sciences Subcommittee for the Protection of Human Subjects; and the research followed the tenets of the Declaration of Helsinski (IRB Protocol Study ID no. 20120897).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors KCF, JL, NAY, HA, NAP, JM, MZ, DM, and HWF have no financial or proprietary interests in the completion of this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"9"}}